Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism

Kathryn M. Meurs, Joshua A Stern, Clarke E. Atkins, Darcy Adin, Brent Aona, Julia Condit, Teresa DeFrancesco, Yamir Reina-Doreste, Bruce W. Keene, Sandy Tou, Jessica Ward, Kathleen Woodruff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The objective of this study was to evaluate angiotensin-converting enzyme (ACE) activity in dogs and with and without an ACE polymorphism in the canine ACE gene, before and after treatment with an ACE inhibitor. Methods: Thirty-one dogs (20 wild-type, 11 ACE polymorphism) with heart disease were evaluated with ACE activity measurement and systolic blood pressure before and after administration of an ACE inhibitor (enalapril). Results: Median pre-treatment ACE activity was significantly lower for ACE polymorphism dogs than for dogs with the wild-type sequence (P=0.007). After two weeks of an ACE inhibitor, ACE activity was significantly reduced for both genotypes (wild-type, P<0.0001; ACE polymorphism P=0.03); mean post-therapy ACE activity was no different between the groups. Conclusion: An ACE polymorphism is associated with lower levels of ACE activity. Dogs with the polymorphism still experience suppression of ACE activity in response to an ACE inhibitor. It is possible that the genetic status and ACE activity of dogs may impact the response of dogs with this variant to an ACE inhibitor.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Volume18
Issue number4
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Peptidyl-Dipeptidase A
Heart Diseases
Dogs
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
Enalapril
Canidae

Keywords

  • angiotensin-converting enzyme
  • canine
  • enalapril
  • Polymorphism

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism. / Meurs, Kathryn M.; Stern, Joshua A; Atkins, Clarke E.; Adin, Darcy; Aona, Brent; Condit, Julia; DeFrancesco, Teresa; Reina-Doreste, Yamir; Keene, Bruce W.; Tou, Sandy; Ward, Jessica; Woodruff, Kathleen.

In: JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, Vol. 18, No. 4, 01.10.2017, p. 1-4.

Research output: Contribution to journalArticle

Meurs, KM, Stern, JA, Atkins, CE, Adin, D, Aona, B, Condit, J, DeFrancesco, T, Reina-Doreste, Y, Keene, BW, Tou, S, Ward, J & Woodruff, K 2017, 'Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism', JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, vol. 18, no. 4, pp. 1-4. https://doi.org/10.1177/1470320317737184
Meurs, Kathryn M. ; Stern, Joshua A ; Atkins, Clarke E. ; Adin, Darcy ; Aona, Brent ; Condit, Julia ; DeFrancesco, Teresa ; Reina-Doreste, Yamir ; Keene, Bruce W. ; Tou, Sandy ; Ward, Jessica ; Woodruff, Kathleen. / Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism. In: JRAAS - Journal of the Renin-Angiotensin-Aldosterone System. 2017 ; Vol. 18, No. 4. pp. 1-4.
@article{a32e4a41a63e43dea9ca130bc1ac6476,
title = "Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism",
abstract = "Objective: The objective of this study was to evaluate angiotensin-converting enzyme (ACE) activity in dogs and with and without an ACE polymorphism in the canine ACE gene, before and after treatment with an ACE inhibitor. Methods: Thirty-one dogs (20 wild-type, 11 ACE polymorphism) with heart disease were evaluated with ACE activity measurement and systolic blood pressure before and after administration of an ACE inhibitor (enalapril). Results: Median pre-treatment ACE activity was significantly lower for ACE polymorphism dogs than for dogs with the wild-type sequence (P=0.007). After two weeks of an ACE inhibitor, ACE activity was significantly reduced for both genotypes (wild-type, P<0.0001; ACE polymorphism P=0.03); mean post-therapy ACE activity was no different between the groups. Conclusion: An ACE polymorphism is associated with lower levels of ACE activity. Dogs with the polymorphism still experience suppression of ACE activity in response to an ACE inhibitor. It is possible that the genetic status and ACE activity of dogs may impact the response of dogs with this variant to an ACE inhibitor.",
keywords = "angiotensin-converting enzyme, canine, enalapril, Polymorphism",
author = "Meurs, {Kathryn M.} and Stern, {Joshua A} and Atkins, {Clarke E.} and Darcy Adin and Brent Aona and Julia Condit and Teresa DeFrancesco and Yamir Reina-Doreste and Keene, {Bruce W.} and Sandy Tou and Jessica Ward and Kathleen Woodruff",
year = "2017",
month = "10",
day = "1",
doi = "10.1177/1470320317737184",
language = "English (US)",
volume = "18",
pages = "1--4",
journal = "JRAAS - Journal of the Renin-Angiotensin-Aldosterone System",
issn = "1470-3203",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism

AU - Meurs, Kathryn M.

AU - Stern, Joshua A

AU - Atkins, Clarke E.

AU - Adin, Darcy

AU - Aona, Brent

AU - Condit, Julia

AU - DeFrancesco, Teresa

AU - Reina-Doreste, Yamir

AU - Keene, Bruce W.

AU - Tou, Sandy

AU - Ward, Jessica

AU - Woodruff, Kathleen

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Objective: The objective of this study was to evaluate angiotensin-converting enzyme (ACE) activity in dogs and with and without an ACE polymorphism in the canine ACE gene, before and after treatment with an ACE inhibitor. Methods: Thirty-one dogs (20 wild-type, 11 ACE polymorphism) with heart disease were evaluated with ACE activity measurement and systolic blood pressure before and after administration of an ACE inhibitor (enalapril). Results: Median pre-treatment ACE activity was significantly lower for ACE polymorphism dogs than for dogs with the wild-type sequence (P=0.007). After two weeks of an ACE inhibitor, ACE activity was significantly reduced for both genotypes (wild-type, P<0.0001; ACE polymorphism P=0.03); mean post-therapy ACE activity was no different between the groups. Conclusion: An ACE polymorphism is associated with lower levels of ACE activity. Dogs with the polymorphism still experience suppression of ACE activity in response to an ACE inhibitor. It is possible that the genetic status and ACE activity of dogs may impact the response of dogs with this variant to an ACE inhibitor.

AB - Objective: The objective of this study was to evaluate angiotensin-converting enzyme (ACE) activity in dogs and with and without an ACE polymorphism in the canine ACE gene, before and after treatment with an ACE inhibitor. Methods: Thirty-one dogs (20 wild-type, 11 ACE polymorphism) with heart disease were evaluated with ACE activity measurement and systolic blood pressure before and after administration of an ACE inhibitor (enalapril). Results: Median pre-treatment ACE activity was significantly lower for ACE polymorphism dogs than for dogs with the wild-type sequence (P=0.007). After two weeks of an ACE inhibitor, ACE activity was significantly reduced for both genotypes (wild-type, P<0.0001; ACE polymorphism P=0.03); mean post-therapy ACE activity was no different between the groups. Conclusion: An ACE polymorphism is associated with lower levels of ACE activity. Dogs with the polymorphism still experience suppression of ACE activity in response to an ACE inhibitor. It is possible that the genetic status and ACE activity of dogs may impact the response of dogs with this variant to an ACE inhibitor.

KW - angiotensin-converting enzyme

KW - canine

KW - enalapril

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85038937790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038937790&partnerID=8YFLogxK

U2 - 10.1177/1470320317737184

DO - 10.1177/1470320317737184

M3 - Article

VL - 18

SP - 1

EP - 4

JO - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

JF - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

SN - 1470-3203

IS - 4

ER -